ArticleDrugs - real world outcomes2024

Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.

Yudai Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.